Letters sent to healthcare professionals in October 2015

In October 2015, letters were sent to healthcare professionals to provide safety information for the anticancer medicines crizotinib and vemurafenib

A letter regarding crizotinib has been sent to inform about the risk of cardiac failure.

A letter regarding vemurafenib has been sent to inform about the risk of potentiation of radiation toxicity.

Article citation: Drug Safety Update Vol 9 issue 4, November 2015: 3.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.